Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

This publication has 13 references indexed in Scilit:

• Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease
  Medical Decision Making, 2002
• Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials
  The Lancet, 2002
• BAYESIAN COST-EFFECTIVENESS ANALYSIS
  International Journal of Technology Assessment in Health Care, 2001
• Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches
  Statistics in Medicine, 2000
• Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)
  Published by Oxford University Press (OUP) ,2000
• Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation
  The Lancet, 1998
• An Introduction to Markov Modelling for Economic Evaluation
  PharmacoEconomics, 1998
• Inpatient deaths from acute myocardial infarction, 1982-92: analysis of data in the Nottingham heart attack register
  BMJ, 1997
• Costs, effects and C/E‐ratios alongside a clinical trial
  Health Economics, 1994
• On the decision rules of cost-effectiveness analysis
  Journal of Health Economics, 1993